Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.52 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.52 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | LTK | P29376 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18136 | 0.89 | GABRA1 (0.56) | GABRA1GABRB2AKR1B1KMT2AMEN1 | |
| SCHEMBL4981097 | 0.84 | GABRA1 (0.48) | GABRA1GABRB2AKR1B1KMT2AMEN1 | |
| SCHEMBL4170461 | 0.83 | GABRA1 (0.50) | GABRA1GABRB2AKR1B1KMT2AMEN1 | |
| SCHEMBL10625097 | 0.81 | GABRA1 (0.48) | GABRA1GABRB2AKR1B1KMT2AMEN1 | |
| Ammonia Solution, Strong SCHEMBL11203810 | 0.81 | GABRA1 (0.48) | GABRA1GABRB2AKR1B1KMT2AMEN1 | |
| SCHEMBL1355189 | 0.80 | GABRA1 (0.52) | GABRA1GABRB2AKR1B1KMT2AMEN1 | |
| SCHEMBL10457216 | 0.80 | GABRA1 (0.53) | GABRA1GABRB2AKR1B1KMT2AMEN1 | |
| SCHEMBL9672897 | 0.79 | GABRA1 (0.47) | GABRA1GABRB2AKR1B1KMT2AMEN1 | |
| SCHEMBL2120821 | 0.79 | GABRA1 (0.68) | GABRA1GABRB2AKR1B1KMT2AMEN1 | |
| SCHEMBL254084 | 0.79 | GABRA1 (0.57) | GABRA1GABRB2AKR1B1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-59152358-A | — | — | None | — | — | JP | disclosed |
| CN-117820076-A | Method for preparing 2, 6-dichlorotoluene by micro-channel reactor | 盐城师范学院 | 2024-04-05 | — | — | CN | disclosed |
| CN-114773145-A | Method for synthesizing 2, 6-dichlorotoluene by directionally chlorinating o-chlorotoluene with novel composite catalyst | 南京工业大学 | 2022-07-22 | — | — | CN | disclosed |
| CN-112513027-A | Indazole amine derivative, preparation method and medical application thereof | 浙江海正药业股份有限公司 | 2021-03-16 | — | — | CN | disclosed |
| WO-2020035019-A1 | INDAZOLE AMINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 浙江海正药业股份有限公司 | 2020-02-20 | — | — | WO | disclosed |
| EP-2217576-B1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | UNIV MICHIGAN (US) | 2016-05-11 | — | — | EP | disclosed |
| US-8759340-B2 | Benzodiazepinone compounds useful in the treatment of skin conditions | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-06-24 | — | — | US | disclosed |
| US-8673897-B2 | Benzodiazepinone compounds and methods of treatment using same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-03-18 | — | — | US | disclosed |
| US-8604023-B2 | 1,4-benzodiazepinone compounds and their use in treating cancer | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-12-10 | — | — | US | disclosed |
| US-20130274197-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-10-17 | — | — | US | disclosed |
| US-20120232067-A1 | BENZODIAZEPINONE COMPOUNDS AND METHODS OF TREATMENT USING SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-09-13 | — | — | US | disclosed |
| EP-2470020-A1 | BENZODIAZEPINONE COMPOUNDS AND METHODS OF TREATMENT USING SAME | The Regents of the University of Michigan (US) | 2012-07-04 | — | — | EP | disclosed |
| US-8188072-B2 | Benzodiazepinone compounds useful in the treatment of skin conditions | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-05-29 | — | — | US | disclosed |
| US-20120094982-A1 | 1,4-BENZODIAZEPINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120040971-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-02-16 | — | — | US | disclosed |
| WO-2011035124-A1 | BENZODIAZEPINONE COMPOUNDS AND METHODS OF TREATMENT USING SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-03-24 | — | — | WO | disclosed |
| EP-2217576-A2 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | The Regents of the University of Michigan (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009061916-A2 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-05-14 | — | — | WO | disclosed |
| US-20090118244-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-05-07 | — | — | US | disclosed |
| JP-S59152358-A | PREPARATION OF N-(ALPHA,ALPHA-DIALKYLBENZYL)PHENYLACETAMIDE DERIVATIVE | IDEMITSU KOSAN CO LTD | 1984-08-31 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040971-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | RORC, RORA, RORB | GABRA1 210/4885GABRB2 231/4885AKR1B1 103/4885 |
| US-20120094982-A1 | 1,4-BENZODIAZEPINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | HTR4, HTR1A, HTR3B | GABRA1 18/4885GABRB2 49/4885AKR1B1 356/4885 |
| US-20090118244-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | RORC, RORA, RORB | GABRA1 210/4885GABRB2 231/4885AKR1B1 103/4885 |
| US-20130274197-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | RORC, RORA, RORB | GABRA1 210/4885GABRB2 231/4885AKR1B1 103/4885 |
| US-20120232067-A1 | BENZODIAZEPINONE COMPOUNDS AND METHODS OF TREATMENT USING SAME | TPH1, GABBR1, RORC | GABRA1 22/4885GABRB2 55/4885AKR1B1 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.